Vaxcyte Reports $212.8 Million Net Loss in Q3 2025, Plans Phase 3 Trials for Vaccine Candidates

Vaxcyte, Inc. reported significant financial results for the third quarter of 2025, with a net loss of $212.8 million, compared to a loss of $103.1 million in the same period last year, marking a 106.4% increase. For the nine months ended September 30, 2025, the net loss was $520.1 million, up from $326.8 million in 2024, reflecting a 59.1% increase. The company's total operating expenses for the third quarter reached $242.4 million, a 73.2% increase from $139.9 million in the prior year, driven primarily by a 79.5% rise in research and development costs, which totaled $209.9 million.

In terms of liquidity, Vaxcyte reported cash and cash equivalents of $281.1 million as of September 30, 2025, down from $387.9 million at the end of 2024. The company also held short-term investments of $1.43 billion, contributing to total assets of $3.17 billion. The accumulated deficit increased to $1.91 billion, indicating ongoing challenges in achieving profitability. The company has not generated any product revenue to date and anticipates continued net losses as it advances its vaccine candidates through clinical trials.

Strategically, Vaxcyte has made notable advancements in its product pipeline, particularly with its pneumococcal conjugate vaccine (PCV) candidates. The company is preparing to initiate a Phase 3 clinical program for its VAX-31 candidate in December 2025, following positive results from earlier studies. Additionally, Vaxcyte has entered into significant manufacturing agreements, including a long-term partnership with Lonza for the construction of a dedicated manufacturing suite in Switzerland and a master services agreement with Thermo Fisher Scientific for drug product supply in North Carolina.

Operationally, Vaxcyte has expanded its workforce, with an increase in employee headcount to support its growing research and development activities. The company is also focusing on enhancing its manufacturing capabilities to meet potential commercial demands. As of September 30, 2025, Vaxcyte had incurred $207.6 million in capital expenditures related to its facility build-out and manufacturing operations. The company expects to continue investing heavily in its vaccine development programs, which are critical to its long-term growth strategy.

Looking ahead, Vaxcyte remains optimistic about its future, with plans to advance its vaccine candidates through clinical trials and pursue regulatory approvals. However, the company acknowledges the need for substantial additional funding to support its operations and development efforts. Vaxcyte's management believes that its current cash reserves will be sufficient to fund operations for at least the next 12 months, but the company will continue to seek additional financing options to ensure the successful commercialization of its vaccine candidates.